Randomized comparisons of bevacizumab(B) and irinotecan(I),added to temozolomide(T), in children with relapsed/refractory high-risk neuroblastoma(RR-HRNB); survival results of the ITCC-SIOPEN beacon-neuroblastoma phase 2 trial
Authors
Wheatley, K.Holt, G.
Owens, C.
Valteau-Couanet, D.
Gambart, M.
Castel, V.
Van Eijkelenburg, N.
Castellano, A.
Nysom, K.
Gerber, N.
Laureys, G.
Ladenstein, R.
Makin, Guy W J
Vaidya, S.
Thebaud, E.
Kearns, P.
Pearson, A.
Moreno, L.
Affiliation
University of Birmingham, Cancer Research Uk Clinical Trials Unit, Birmingham, United KingdomIssue Date
2020